Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment

Clinical Biochemistry

Volumn 42, Issue 10-11, 2009, Pages 1076-1081

  Barim, Abdullah Onder ^a   Aydin, Suleyman ^a   Colak, Ramis ^a   Dag, Ersel ^b   Deniz, Omer ^c   Sahin, Ibrahim ^a  

^a FIRAT UNIVERSITY   (Turkey)

^b Elazig Research and Education Hospital ^*  (Turkey)

^c Elazig Hospital for Mental Disorders   (Turkey)

Author keywords

Arylesterase; Ghrelin; Major depression; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CHOLESTEROL; CITALOPRAM; GHRELIN; LIPID; TRIACYLGLYCEROL;

ACYLATION; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; PATHOGENESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SPECTROPHOTOMETRY; TREATMENT DURATION; TREATMENT OUTCOME;

ACYLATION; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; CITALOPRAM; DEMOGRAPHY; DEPRESSIVE DISORDER; FEMALE; GHRELIN; HUMANS; MALE;

EID: 67349287047     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.02.020     Document Type: Article

References (46)

1. Ozturk M.O. Ruh Saǧli{dotless}ǧi{dotless} ve Bozukluklari{dotless} (1997), Hekimler Yayi{dotless}n Birliǧi, Ankara 226-227
2. Eker E. Depresyon, Somatizasyon ve Psikiyatrik Aciller (1999), İ.Ü. Cerrahpaşa Ti{dotless}p Fakültesi Sürekli Ti{dotless}p Eǧitimi Komisyonu, İstanbul 13
3. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-659
4. Dagli A.F., Aydin S., Karaoglu A., Akpolat N., Ozercan I.H., and Ozercan M.R. Ghrelin expression in normal kidney tissue and renal carcinomas. Pathol Res Pract 205 3 (2009) 165-173
5. Aydin S. Discovery of ghrelin hormone: research and clinical applications. Turk. J. Biochem. 32 (2007) 76-89
6. Kojima M., and Kangawa K. Ghrelin: structure and function. Physiol. Rev. 85 (2005) 495-522
7. Brunetti L., Recinella L., Orlando G., Michelotto B., Di Nisio C., and Vacca M. Effects of ghrelin and amylin on dopamine, norepinephrine and serotonin release in the hypothalamus. Eur. J. Pharmacol. 454 (2002) 189-192
8. Hyttel J. Citalopram: pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuropsychopharmacol. Biol. Psychiatry 6 (1982) 277-295
9. Bezchlibnyk-Butler K., Aleksic I., and Kennedy S.H. Citalopram: a review of pharmacological and clinical effects. J. Psychiatry Neurosci. 25 (2000) 241-254
10. Träskman-Bendz L., Asberg M., Bertilsson L., and Thorén P. CSF monoamine metabolites of depressed patients during illness and after recovery. Acta Psychiatr. Scand. 69 (1984) 333-342
11. Sullivan G.M., Mann J.J., Oquendo M.A., Lo E.S., Cooper T.B., and Gorman J.M. Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol. Psychiatry 60 (2006) 500-506
12. Vaswani M., Linda F.K., and Ramesh S. Role of SSRI in psychiatric disorder. Prog. Neuropsychopharmacol. Biol. Psy. 27 (2003) 85-102
13. De Vriese C., Hacquebard M., Gregoire F., Carpentier Y., and Delporte C. Ghrelin interacts with human plasma lipoproteins. Endocrinology 148 (2007) 2355-2362
14. Uriel A. Characterization of cholinesterase and other carboxylic esterases after electrophoresis and immunoelectrophoresis on agar. I. Application to the study of esterases of normal human serum. Am. Instit. Pasteur. 101 (1961) 104-119
15. Mackness M.I., Halam S.D., Peard T., Warner S., and Walker C.H. The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp. Biochem. Physiol. B. 82 (1985) 675-677
16. Kumru S., Aydin S., Gursu M.F., and Ozcan Z. Changes of serum paraoxonase (an HDL-cholesterol-associated lipophilic antioxidant) and arylesterase activities in severe preeclamptic women. Eur. J. Obstet. Gynecol. Reprod. Biol. 114 (2004) 177-181
17. Ng C.J., Wadleigh D.J., Gangopadhyay A., et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276 (2001) 44444-44449
18. Mackness B., Durrington P.N., and Mackness M.I. Human serum paraoxonase. Gen. Pharmacol. 31 (1998) 329-336
19. Mackness M.I., Arrol S.I., Mackness B., and Durrington P.N. Alloenzymes of paraoxonase and effectiveness of high density lipoproteins in protecting low density lipoprotein against lipid peroxidation. The Lancet 349 (1997) 851-852
20. La Du B.N., Aviram M., Billecke S., and Navab M. On the physical role(s) of the paraoxonases. Chem-Biol. Inter. 14 (1999) 379-388
21. Paz E., Hermida J., Bouzas L., Brenlla J., and Tutor J.C. LDL cholesterol estimation using the Anandaraja's and Friedewald's formulas in schizophrenic patients treated with antipsychotic drugs. Clin. Biochem. 41 (2008) 1002-1007
22. Palik E., Birkas K.D., Faludi G., Karadi I., and Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res. Clin. Pract. 68 (2005) 60-64
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994) Washington D.C.
24. Eckerson H.W., Wyte M.C., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35 (1983) 1126-1138
25. Haagen L., and Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur. J. Clin. Chem. Clim. Biochem. 30 (1992) 391-395
26. Horoz M., Aslan M., Selek S., et al. PON1 status in haemodialysis patients and the impact of hepatitis C infection. Clin. Biochem. 40 (2007) 609-614
27. Cummings D.E. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol. Behav. 89 (2006) 71-84
28. Tschöp M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., and Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (2001) 707-709
29. Ozdemir E., Cetinkaya S., Ersan S., Kucukosman S., and Ersan E.E. Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (2009) 62-65
30. El Eter E., Al Tuwaijiri A., Hagar H., and Arafa M. In vivo and in vitro antioxidant activity of ghrelin: attenuation of gastric ischemic injury in the rat. J. Gastroenterol. Hepatol. 22 (2007) 1791-1799
31. Gur M., Yildiz A., Demirbag R., et al. Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and their relationship with oxidative stress markers. Coron. Artery Dis. 18 (2007) 89-95
32. Sarandol A., Sarandol E., Eker S.S., et al. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 1103-1108
33. Bauters C., Amant C., Boullier A., et al. Paraoxonase polymorphism (Gln192Arg) as a determinant of the response of human coronary arteries to serotonin. Circulation 101 (2000) 740-743
34. Demirsoy A. Kali{dotless}ti{dotless}m ve Evrim. Ankara (2000) 795-829
35. Horsten M., Wamala S.P., Vingerhoets A., and Orth-Gomer K. Depressive symptoms, social support, and lipid profile in healthy middleaged women. Psychosom. Med. 59 (1997) 521-528
36. Maes M., Christophe A., Delanghe J., Altamura C., Neels H., and Meltzer H.Y. Lowered omega 3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 85 (1999) 275-291
37. Selvi Y., İnci R., Kiran U.K., Agargun M.Y., Ozer O.A., and Eryonucu B. Postpartum depression and serum cholesterol level. Clinical Psychiatry 7 (2004) 48-50
38. Agargun M.Y. Serum cholesterol concentration, depression, and anxiety. Acta Psychiatr. Scand. 105 (2002) 81-83
39. Agargun M.Y., Sekeroglu M.R., Kara H., et al. Sleep-related violence and low serum cholesterol: a preliminary study. Psychiatry Clin. Neurosci. 56 (2002) 195-198
40. Kirpinar, Caykoylu A., Coskun I., Sevimli F., and Altuntas N. Serum cholesterol and triglyceride levels in depression. Turkish Journal of Psychiatry 9 (1998) 23-27
41. McCallum J., Simons L., Simons J., and Friedlander Y. Low serum cholesterol is not associated with depression in the elderly: data from an Australian community study. Aust. N. Z. J. Med. 24 (1994) 561-564
42. Engelberg H. Low serum cholesterol and suicide. Lancet 339 (1992) 727-729
43. Oxenrug G.F., Branconnier R.J., Harto-Traux N., and Cole J.O. Is serum cholesterol a biological marker for major depressive episode?. Am. J. Psychiatry 140 (1983) 920-921
44. Yates W.R., and Wallace R. Cardiovascular risk factors in affective disorder. J. Affective Dis. 12 (1987) 129-134
45. Sayar K., Acar B., and Atinc N. Cholesterol levels in major depression. Bull. Clin. Psychopharmacol. 8 (1998) 104-108
46. Buydens-Branchey L., Branchey M., Hudson J., and Fergeson P. Low HDL cholesterol, aggression and altered central serotonergic activity. Psychiatry Res. 93 (2000) 93-102